MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41408-023-00794-x

Медицинская библиотека · Blood cancer journal · 2023

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

Fonseca Rodrigo, Arribas Mariano, Wiedmeier-Nutor Julia E, Kusne Yael N, González Vélez Miguel, Kosiorek Heidi E, Butterfield Richard Duke J, Kirsch Ilan R, Mikhael Joseph R, Stewart A Keith, Reeder Craig, Larsen Jeremy, Bergsagel P Leif, Fonseca Rafael

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in combination with functional imaging remains to be validated. We performed a retrospective analysis on MM patients who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT with NGS-MRD and positron emission tomography (PET-CT). Patients with ≥ 2 MRD measurements were included in a secondary analysis for sequential measurements. 186 patients were included. At day 100, 45 (24.2%) patients achieved MRD negativity at a sensitivity threshold of 10-6. MRD negativity was the most predictive factor for longer time to next treatment (TTNT). Negativity rates did not differ according to MM subtype, R-ISS Stage nor cytogenetic risk. PET-CT and MRD had poor agreement, with high rates of PET-CT negativity in MRD-positive patients. Patients with sustained MRD negativity had longer TTNT, regardless of baseline risk characteristics. Our results show that the ability to measure deeper and sustainable responses distinguishes patients with better outcomes. Achieving MRD negativity was the strongest prognostic marker and could help guide therapy-related decisions and serve as a response marker for clinical trials.

Для цитирования: Fonseca Rodrigo, Arribas Mariano, Wiedmeier-Nutor Julia E, Kusne Yael N, González Vélez Miguel, Kosiorek Heidi E, Butterfield Richard Duke J, Kirsch Ilan R, Mikhael Joseph R, Stewart A Keith, Reeder Craig, Larsen Jeremy, Bergsagel P Leif, Fonseca Rafael. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.. Blood cancer journal. 2023. DOI: 10.1038/s41408-023-00794-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.